European Journal of Clinical Microbiology & Infectious Diseases最新文献

{"title":"Epidemiological characteristics of Helicobacter pylori infection and antibiotic resistance in urban areas of Guangdong Province, China: a multi-center, cross-sectional surveillance.","authors":"Luhua Xian, Yuting Si, Luan Luan, Jinxin Lai, Jiawei Tang, Liang Wang","doi":"10.1007/s10096-025-05105-9","DOIUrl":"https://doi.org/10.1007/s10096-025-05105-9","url":null,"abstract":"<p><strong>Purpose: </strong>Helicobacter pylori (H. pylori) infection is widespread globally and can cause serious gastrointestinal complications, including gastric cancer. This study assesses the prevalence and antibiotic resistance of H. pylori in Guangdong, one of China's most developed provinces.</p><p><strong>Methods: </strong>A multi-center, cross-sectional study was conducted across six cities in Guangdong provinces, that is, Guangzhou, Shenzhen, Heyuan, Foshan, Yunfu, and Zhaoqing. Non-invasive gastric fluid samples were collected via the string test, and H. pylori infection and antibiotic resistance were detected using quantitative PCR. Risk factors for infection were analyzed.</p><p><strong>Results: </strong>Of 1,764 participants, 444 (25.17%) tested positive for H. pylori, with the highest infection rate in Foshan (29.81%). Antibiotic resistance testing of these 444 infected individuals revealed that, except for levofloxacin resistance in Yunfu (14.29%), clarithromycin resistance in Yunfu and resistance to other antibiotics in all cities exceeded the 15% threshold. Infection rates were significantly higher in males (OR 1.29, 95% CI 1.03-1.60, p = 0.03) and obese individuals (OR 2.04, 95% CI 1.04-3.91, p = 0.03), with obesity identified as an independent risk factor.</p><p><strong>Conclusion: </strong>This study provides a comprehensive update on the prevalence, antibiotic resistance, and risk factors of H. pylori infection in Guangdong, offering valuable insights for public health strategies aimed at improving diagnosis and treatment.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of imipenem-relebactam susceptibility testing in carbapenem resistant Pseudomonas aeruginosa: comparison of sensititre microplates, disc diffusion, and MTS gradient strips with broth microdilution.","authors":"Adrien Biguenet, Léa Devoos, Julie Rousselot, Maxime Bour, Damien Fournier, Katy Jeannot","doi":"10.1007/s10096-025-05058-z","DOIUrl":"https://doi.org/10.1007/s10096-025-05058-z","url":null,"abstract":"<p><p>Four commercial tests EUMDROXF^® Sensititre microplates, MTS gradient strips, and disc diffusion were evaluated for imipenem-relebactam susceptibility in 148 ceftazidime and imipenem-resistant Pseudomonas aeruginosa strains, using broth microdilution (BMD) as the reference. EUMDROXF^® Sensititre microplates showed the highest accuracy (CA = 93.2%, EA = 93.9%, and bias difference + 21.8%). While the MTS gradient strips showed acceptable performance (CA = 84.5%; EA = 89.9%, and difference of bias = 21.0%), the disc method misclassified 25.8% (16/62) of the resistant strains. Given these results, considering an Area of Technical Uncertainty (ATU) for disc diffusion (20-24 mm) in imipenem-relebactam testing is recommended for P. aeruginosa strains.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance evaluation of a novel MBT LipidART module (Bruker Daltonics) for detection of colistin resistance in Escherichia coli and Klebsiella pneumoniae.","authors":"Julija Germ, Mateja Pirs","doi":"10.1007/s10096-025-05099-4","DOIUrl":"https://doi.org/10.1007/s10096-025-05099-4","url":null,"abstract":"<p><p>We evaluated the MBT LipidART module on a MALDI Biotyper® Sirius System (Bruker Daltonics) for the rapid detection of colistin resistance in Escherichia coli (EC) and Klebsiella pneumoniae (KPN) by analysing lipid A profiles in negative ion mode. Categorical agreement was achieved for 98.3% EC (N = 58) and 85.0% KPN (N = 40). Challenges included calibration difficulties, limited availability of compatible equipment and issues with mucoid and adherent KPN isolates that yielded invalid results. While MBT LipidART module shows promise as a rapid tool for detection of colistin resistance, its performance was notably better for EC compared to KPN.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.","authors":"Matteo Boattini, Paolo Gaibani, Sara Comini, Cristina Costa, Rossana Cavallo, Francesco Broccolo, Gabriele Bianco","doi":"10.1007/s10096-025-05080-1","DOIUrl":"https://doi.org/10.1007/s10096-025-05080-1","url":null,"abstract":"<p><p>The carbapenemase-producing Gram-negative organisms represent an urgent clinical and public health concern, as they have been associated with increased mortality and high dissemination in healthcare settings. Although overall incidence rates of infections sustained by metallo-β-lactamase (MβL)-producers have remained lower than those sustained by other carbapenemase-producers, albeit with substantial geographic differences, a significant increase in the prevalence of MβL-producers has been observed over the last decade. The recent development of new antimicrobials expanded the armamentarium to counter the challenge of metallo-β-lactamase (MβL)-producers. Cefiderocol and aztreonam/avibactam are already clinically available and recommended by international guidelines. In addition, two new classes of β-lactam/ β-lactamase combinations are under clinical evaluation: (i) combination of β-lactam with novel boronic-derived inhibitors (e.g. taniborbactam and xeruborbactam), (ii) combination of β-lactam with last generation diazabicyclooctane β-lactamase inhibitors (e.g. zidebactam and nacubactam), active on most of serine-β-lactamases but also showing strong intrinsic activity on PBP-2. This review aims to provide up-to-date data on the characteristics, activity and emerging resistance mechanisms of the armamentarium of clinically available or soon-to-be introduced drugs for the treatment of MβL-producing Gram-negative organisms.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Schistosomiasis trends and control efforts: a global perspective from 1990 to 2050.","authors":"Bahe Dong, Zhiyong Hou, Keqiang Lu","doi":"10.1007/s10096-025-05102-y","DOIUrl":"https://doi.org/10.1007/s10096-025-05102-y","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Schistosomiasis is a chronic parasitic disease primarily endemic to tropical and subtropical regions, posing significant challenges to public health and economic development. Despite progress in global control efforts, the disease continues to be a major public health concern in high-burden countries such as China, Brazil, and Nigeria. This study seeks to assess the effectiveness of schistosomiasis control measures in these countries and on a global scale.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;To analyze and visualize the distribution of schistosomiasis burden, data from the Global Burden of Disease (GBD) database for 2021 covering 204 countries were utilized. Statistical information on fatalities and Disability-Adjusted Life Years (DALYs) related to schistosomiasis from 1990 to 2021 was extracted, encompassing global, African, Asian, and American regions, as well as specific data for the countries of China, Brazil, and Nigeria. The Bayesian Average Annual Percentage Change (BAPC) model was applied for forecasting trends. Decomposition analysis was performed to assess the contributions of various factors to changes in disease burden, and the Annual Average Percentage Change (AAPC) was calculated using the Joinpoint model.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Data from the GBD database reveal that the burden of schistosomiasis-related diseases is predominantly concentrated in Africa, Asia, and South America. In 2021, schistosomiasis-related DALYs in China and Brazil ranked 5th and 8th globally, respectively, while fatalities ranked 5th and 6th. Notably, schistosomiasis in Nigeria causes the highest DALYs and deaths globally. From 1990 to 2021, the AAPC in the burden of schistosomiasis-related diseases was negative globally, as well as in Africa, Asia, the Americas, and key countries such as China, Brazil, and Nigeria, with China showing the most significant decline. Between 2017 and 2021, the AAPC remained negative, with Africa registering the lowest AAPC during this period. Decomposition analysis identified population size, growth, and aging as the primary drivers of the increasing disease burden. In contrast, improvements in epidemiological factors, including reductions in incidence, case fatality rates and disease severity, partially countered this trend. Projections indicate that by 2050, the global burden of schistosomiasis will gradually decline, with China and Nigeria expected to achieve the lowest infection rates. However, Brazil is expected to experience a relatively slower decline.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This study analyzes the global burden of schistosomiasis from 1990 to 2021, showing an overall declining trend. While significant progress has been made in control measures in countries such as China, Brazil, and Nigeria, Nigeria remains the most severely affected, with the highest global DALYs and death tolls attributed to schistosomiasis. Despite the overall decline in disease burden, factors such as po","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid diagnosis of urinary tract infection with miniaturised point-of-care cultivation on a dipstick.","authors":"Emre Iseri, Gino Jakobsson, Sofia Bertling, Volkan Özenci, Oskar Ekelund, Wouter van der Wijngaart, Alex van Belkum","doi":"10.1007/s10096-025-05088-7","DOIUrl":"https://doi.org/10.1007/s10096-025-05088-7","url":null,"abstract":"<p><strong>Purpose: </strong>Urinary Tract InfectionAQ1 (UTI) affects over 400 million people annually and globally and is a major reason for empiric antibiotic prescription by general practitioners (GPs).</p><p><strong>Background: </strong>A problem related to microbiological UTI diagnosis is the current lack of point of care (POC) diagnostics. In addition, remote settings, including low and middle income countries (LMIC), are hard to service. Compliance with requirements posed by the In Vitro Diagnostic Regulation (IVDR) and adherence to guidelines as defined by professional user groups are mandatory to pursue. In addition, the World Health Organisation (WHO) promotes optimization of antimicrobial use and more adequate microbiological diagnostics to cure UTI and combat antimicrobial resistance (AMR).</p><p><strong>Methods: </strong>Miniaturised chromogenic bacterial cultivation including rapid antimicrobial susceptibility testing (RAST) at the POC can be successfully used for the diagnosis of UTI. Using small and cost-effective dipsticks containing chromogenic cultivation media, UTI-causing bacteria can be detected, quantified and identified with good sensitivity and specificity.</p><p><strong>Conclusion: </strong>Access to such trustworthy, easy-to-use and cost-efficient diagnostic tools at the POC would offer more timely results for optimised antibiotic treatment. This will improve UTI therapy and prevent AMR.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Voriconazole in the treatment of pediatric patients with hematologic malignancies and invasive fungal infections: a real-world study.","authors":"Namei Wu, Lili Cai, Qingquan Zhang, Yaxin Fan, Zhihang Lin","doi":"10.1007/s10096-025-05067-y","DOIUrl":"https://doi.org/10.1007/s10096-025-05067-y","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the factors influencing voriconazole (VRC) administration, clinical efficacy, and safety in children with hematological malignancies (HM) and invasive fungal infection (IFD).</p><p><strong>Methods: </strong>This is a single-center, retrospective real-world study conducted between July 2018 and December 2023. Univariate and multivariate logistic regression analysis were used to analyze the affecting factors.</p><p><strong>Results: </strong>A total of 167 patients were included in this study. Among them, 13.77% (23/167) of children under 2 years old received off-label use of VRC, with an initial maintenance dose higher than that of other groups (P < 0.001). There were 8 cases (4.79%) of cured, 148 cases (88.62%) of improved, and 11 cases (6.59%) of ineffective. Thirty-eight cases experienced adverse drug reactions (ADR), with a highest incidence (10.2%) of hepatotoxicity. The concomitant proton pump inhibitors (PPIs), days of central venous catheterization and coagulopathy were independent influencing factors of ADR. Sixty-six patients underwent therapeutic drug monitoring (TDM), which increased the probability of achieving the target plasma trough concentration (C_min). Among children < 2 years old underwent TDM, 88.89% (8/9) achieved therapeutic concentration, and the probability was higher than that of the older groups. Days of VRC treatment had a positive but not statistically significant effect on achievement of target C_min. Hypoalbuminemia and days of antimicrobials treatment were independent influencing factors of C_min distribution.</p><p><strong>Conclusion: </strong>Attention to the off-label use of VRC in children < 2 years old, hypoalbuminemia and coagulopathy correction, potential drug interactions with VRC, and ADR monitoring is crucial for clinical efficacy and safety.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of time to positivity in bloodstream infections: an analysis of a population-based cohort in Queensland, Australia.","authors":"Felicity Edwards, Michael Waller, Kevin B Laupland","doi":"10.1007/s10096-025-05096-7","DOIUrl":"10.1007/s10096-025-05096-7","url":null,"abstract":"<p><strong>Purpose: </strong>Time to Positivity (TTP) measures the interval from incubation to bacterial growth detection in blood cultures. Although shorter TTP is associated with higher mortality, factors associated with TTP remain uncertain.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted among Queensland residents with positive blood cultures between 2000-2019. Incident bloodstream infections (BSIs) were identified using Pathology Queensland data, with demographic, clinical, and outcome data linked to state-wide databases.</p><p><strong>Results: </strong>The study analysed 84,341 patients with monomicrobial BSI with a median patient age of 65.6 years (IQR 45.4-78.1), and most infections being community-associated (77.0%). Age showed a non-linear relationship with TTP, and male sex was linked with slightly higher TTP (Incidence Rate Ratio (IRR) 1.01; 95% Confidence Intervals (CI) 1.00-1.02; p = 0.011), reflecting a small but measurable association. Liver disease and malignancy were associated with lower TTP (IRR 0.93; 95% CI 0.91-0.95; p < 0.0001 and IRR 0.95; 95% CI 0.94-0.97; p < 0.0001 respectively), whilst diabetes showed no significant difference (IRR 1.01; 95% CI 1.00-1.02; p = 0.0840). Hospital onset infections exhibited longer TTPs (IRR 1.09; 95% CI 1.08-1.10; p < 0.0001).</p><p><strong>Conclusions: </strong>There are several host characteristics associated with TTP that may in part explain the complex relationship between this variable and mortality. Beyond microbiological factors such as isolate type, TTP is also influenced by clinical variables including patient demographics and infection characteristics highlighting its potential as a prognostic marker. Further evaluation is needed to clarify its role in predicting patient outcomes and guiding tailored treatment strategies.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacodynamic target attainment of the synergism of ceftazidime-avibactam in combination with amikacin against OXA-producing extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa.","authors":"Yixin Kang, Junchang Cui","doi":"10.1007/s10096-025-05090-z","DOIUrl":"10.1007/s10096-025-05090-z","url":null,"abstract":"<p><p>To investigate the pharmacodynamic target attainment of ceftazidime-avibactam (CZA) in combination with amikacin against OXA-producing extensively drug-resistant/ pan-drug-resistant Pseudomonas aeruginosa (XDR/PDR-PA). The minimum inhibitory concentrations (MICs) of CZA and amikacin against OXA-producing XDR/PDR-PA were determined by the checkerboard method, and the combined inhibitory index (FICI) was calculated to evaluate whether the combination of the two antimicrobials has a synergistic effect on OXA-producing XDR/PDR-PA in vitro. The pharmacokinetic (PK) and pharmacodynamic (PD) parameters of CZA and amikacin were combined by Monte Carlo simulation (MCS) to evaluate the cumulative fraction of response (CFR) of the two antimicrobials for the treatment of OXA-producing XDR/PDR-PA infection. The results of synergy tests of CZA in combination with amikacin suggested that 77.3% of XDR/PDR-PA showed synergistic effects. When the PK/PD target was greater than 50, CFR was 97.84% for CZA 2.5 g q8h when CZA in combination with amikacin. CZA in combination with AMK has a synergistic effect in vitro and could be a potential option for treating OXA-producing XDR/PDR-PA infections.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of rapid identification by MALDI-TOF MS from positive blood cultures in Enterococcus spp. bloodstream infections.","authors":"Diogo Lopes, Bruno Grandbastien, Christina Orasch, Gilbert Greub, Antony Croxatto, Guy Prod'Hom, Benoit Guery","doi":"10.1007/s10096-025-05084-x","DOIUrl":"10.1007/s10096-025-05084-x","url":null,"abstract":"<p><strong>Purpose: </strong>Regarding bloodstream infections (BSI) Enterococcus spp. rank among the top five most common organisms. Due to enterococci intrinsic resistance, empiric antibiotic therapy is often inappropriate and early identification becomes crucial. Our objective was to assess the clinical impact of MALDI-TOF identification directly from positive blood cultures (BC) in Enterococcus spp. BSI (E-BSI).</p><p><strong>Methods: </strong>A retrospective cohort study included all adult patients with E-BSI from 2010 to 2017 in a tertiary hospital. ID consultation within 48 h and MALDI-TOF identification directly from BC within 24 h were inclusion criteria. The primary outcome was antimicrobial treatment change following MALDI-TOF and secondary outcomes included 30-day and 1-year mortality, length of stay (LOS) and antimicrobial de-escalation.</p><p><strong>Results: </strong>Among 267 BSI episodes, E. faecalis was isolated in 130 episodes (48.7%), E. faecium in 122 (45.7%), and 104 (39%) were polymicrobial. Empiric antibiotic therapy was inappropriate in 60.3% of patients. The LOS was 36 (IQR 20-64) days, 30-day and 1-year mortality were 16.1% and 43.4%, respectively. Enterococci identification with MALDI-TOF at the species level was possible in 66.3% cases and in 73% of monomicrobial cases. Antibiotics were changed in 85.3% of the former vs. 63.3% in remaining patients (p < 10^- 4), and de-escalation occurred in 35% of subjects (vs. 12.2%,p = 10^- 4). Changing antibiotics after correct identification was associated with a shorter LOS. In multivariate analysis, appropriate antibiotic therapy before MALDI-TOF was protective against 30-day mortality (aOR 0.40(0.08-1.96)), and appropriate antibiotic therapy afterwards against 1-year mortality (aOR 0.21(0.05-0.84)).</p><p><strong>Conclusion: </strong>In E-BSI, direct MALDI-TOF identification from positive BC has a significant clinical impact due to a more frequent antibiotic spectrum correction and de-escalation. This may improve patient outcomes, reducing LOS and potentially mortality.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}